NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company ...

Neurizon Therapeutics (ASX:NUZ) has shared an update on its preparations for its HEALEY ALS Platform Trial – a multicentre, ...

ASX health stocks broke their losing streak this week, while it was a big week for Nanosonics, Neurizon and Sigma.

Watch the video to see the initiatives Neurizon is taking. This video was developed in collaboration with Neurizon ...

In a report released today, Iain Wilkie from Morgans maintained a Buy rating on Pharmaust Limited (ECQ0 – Research Report), with a price target of A$0.42. The company’s shares closed last ...

Neurizon Therapeutics has submitted a formal request to the US FDA for advice on pharmacokinetic studies needed to lift hold on its IND application for NUZ-001 Neurizon Therapeutics (ASX ...

Followed categories will be added to My News. Neurizon Therapeutics (ASX: NUZ) announced last month that the regulator had requested additional animal exposure data be provided to assess adequacy ...